PolyMedix Inc., of Radnor, Pa., added Stephen T. Sonis to its scientific advisory board.
Progenitor Cell Therapy, of New York, named Timothy Fong vice president of technology and product development and appointed David O'Neill director of R&D.
Prosonix, of Oxford, UK, added Ken Cunningham to its board and named Peter Barnes, Marianne Mann and John Pritchard to its new scientific advisory board chaired by Ken Cunningham.
ProtAffin AG, of Graz, Austria, appointed Mike Bartley chief development officer.
Proteostasis Therapeutics, of Cambridge, Mass., appointed Mark J. Enyedy CEO.
Protox Therapeutics Inc., of San Diego, appointed Alexander Casdin chief financial officer.
Reata Pharmaceuticals Inc., of Irving, Texas, added several new management positions: Paul Audhya as vice president of development and chief medical officer; Hilary Malone as vice president and chief regulatory and compliance officer; Sean Nolan as vice president and chief commercial officer; and Jim Rouse as vice president and chief information officer. The firm also added Nancy Wysenski to its board.
Redwood Bioscience, of Emeryville, Calif., appointed Peter Van Vlasselaer executive chairman.
S1 Pharmaceuticals Inc., of Jersey City., N.J., appointed Robert Taylor Segraves and Robert Pyke to its scientific advisory board.
Soligenix Inc., of Princeton, N.J., named Jeffrey Hyams, James Markowitz and Joel Rosh to its medical advisory board.
Spectrum Pharmaceuticals Inc., of Henderson, Nev., appointed Brian Holzer executive director of brand management.
Sucampo Pharmaceuticals Inc., of Bethesda, Md., appointed Cary J. Claiborne chief financial officer.
Synthetic Genomics Vaccines Inc., of La Jolla, Calif., appointed Sammy J. Farah president.
Tengion Inc., of East Norriton, Pa., appointed Scott Flora to its board.
Threshold Pharmaceuticals Inc., of South San Francisco, appointed Nipun Davar vice president of pharmaceutical development and manufacturing.
Tranzyme Pharma Inc., of Research Triangle Park, N.C., appointed Franck Rousseau chief medical officer.
Trimel Pharmaceuticals Corp., of Toronto, appointed John Friedrichsen to its board.
Vanda Pharmaceuticals Inc., of Rockville, Md., named Bob Repella senior vice president and chief commercial officer.
Vermillion Inc., of Austin, Texas, named Donald Munroe chief scientific officer and vice president of R&D.
YM BioSciences Inc., of Mississauga, Ontario, proposed Catherine Mackey for nomination to its board.
Zafgen Inc., of Cambridge, Mass., named Frances K. Heller to its board.